Treatment Information

Back

Non-Hodgkin's Lymphoma treatment details. Biologic therapy.

Stanford University, Stanford, CA, United States.

Survival: monthsCountry:United States
Toxiciy Grade:4City/State/Province:Stanford, CA
Treatments:Biologic therapyHospital:Stanford University
Drugs:Journal:Link
Date:Jul 2013

Description:

Patients:
This phase 2 study involved 14 recurrent diffuse large B cell lymphoma patients who had been previously treated. The median patient age was 69.5 years and 9 were male.

Treatment:
Patients were treated with the biologic therapy agent sorafenib, which is a protein kinase inhibitor that is involved in the growth of cancer cells.

Toxicities:
The most severe toxicities were of grade 4 and included fatigue and low platelet count. Grade 3 rash and diarrhea were also reported.

Results:
The median overall survival was 9 months.

Support:
One of the authors of the study is employed by the Roche-Genentech pharmaceutical company.

Correspondence: Dr. Daniel R Greenwald; email: [email protected]



Back